The company's ctDx lung cancer assay identifies a variety of different actionable mutations in the blood of non-small cell lung cancer patients.
Mascots will distribute Lucence's blood-based tests, which detect DNA fragments shed by a tumor, in order to identify cancer-driving mutations.
Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.
The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.
The test is a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.
Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.
In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.